
Jun 4, 2026
Alnylam, Inceptive ink AI deal potentially worth $2B
Alnylam Pharmaceuticals has announced a significant collaboration with Inceptive Nucleics, aiming to leverage artificial intelligence (AI) for the accelerated discovery of RNA-based therapies. The initial phase of the partnership includes a $30 million investment, with potential total deal value reaching $2 billion contingent on meeting various milestones.This partnership is a key component of Alnylam's broader "Alnylam 2030" strategy, which focuses on expanding its pipeline of innovative therap









